MX2012009224A - Compuestos en calidad de antagonistas de bradiquinina-b1. - Google Patents
Compuestos en calidad de antagonistas de bradiquinina-b1.Info
- Publication number
- MX2012009224A MX2012009224A MX2012009224A MX2012009224A MX2012009224A MX 2012009224 A MX2012009224 A MX 2012009224A MX 2012009224 A MX2012009224 A MX 2012009224A MX 2012009224 A MX2012009224 A MX 2012009224A MX 2012009224 A MX2012009224 A MX 2012009224A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- bradykinin
- antagonists
- preparation
- salts
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 101800004538 Bradykinin Proteins 0.000 title 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 title 1
- 102100035792 Kininogen-1 Human genes 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C211/54—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to two or three six-membered aromatic rings
- C07C211/56—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to two or three six-membered aromatic rings the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Objeto de la presente invención son los compuestos de la fórmula general I (ver fórmulas) en la que n, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 y X se definen como se describe posteriormente, sus enantiómeros, sus diastereoisómeros, sus mezclas y sus sales, en especial sus sales fisiológicamente tolerables con ácidos o bases orgánicos o inorgánicos, que presentan valiosas propiedades, su preparación, los medicamentos que contienen los compuestos farmacológicamente eficaces, su preparación y su uso.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2010/052232 WO2010097372A1 (de) | 2009-02-26 | 2010-02-23 | Verbindungen als bradykinin-b1-antagonisten |
| PCT/EP2011/052512 WO2011104203A1 (de) | 2010-02-23 | 2011-02-21 | Verbindungen als bradykinin-b1-antagonisten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012009224A true MX2012009224A (es) | 2012-08-23 |
Family
ID=43981434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012009224A MX2012009224A (es) | 2010-02-23 | 2011-02-21 | Compuestos en calidad de antagonistas de bradiquinina-b1. |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP2539323B3 (es) |
| JP (1) | JP5603955B2 (es) |
| KR (1) | KR101843341B1 (es) |
| CN (2) | CN102781916B (es) |
| AP (1) | AP3218A (es) |
| AR (1) | AR080249A1 (es) |
| AU (1) | AU2011219885C1 (es) |
| CA (1) | CA2790952C (es) |
| CY (1) | CY1116182T1 (es) |
| DK (1) | DK2539323T6 (es) |
| ES (1) | ES2531663T7 (es) |
| IL (1) | IL220680A (es) |
| MA (1) | MA34008B1 (es) |
| MX (1) | MX2012009224A (es) |
| NZ (1) | NZ601194A (es) |
| PE (1) | PE20121805A1 (es) |
| PL (1) | PL2539323T6 (es) |
| PT (1) | PT2539323E (es) |
| SG (1) | SG183336A1 (es) |
| SI (1) | SI2539323T1 (es) |
| TW (1) | TWI499589B (es) |
| WO (1) | WO2011104203A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007034620A1 (de) | 2007-07-25 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue B1-Antagonisten |
| JP5238812B2 (ja) | 2007-08-29 | 2013-07-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ブラジキニンｂ１アンタゴニスト |
| ES2531663T7 (es) | 2010-02-23 | 2018-02-13 | Boehringer Ingelheim International Gmbh | Compuestos en calidad de antagonistas de bradiquinina B1 |
| WO2012022794A1 (de) * | 2010-08-20 | 2012-02-23 | Boehringer Ingelheim International Gmbh | Pyridazinderivative als bradykinin b1 rezeptor antagonsiten |
| US8937073B2 (en) | 2010-08-20 | 2015-01-20 | Boehringer Ingelheim International Gmbh | Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists |
| JP7376582B2 (ja) * | 2018-10-22 | 2023-11-08 | イーオーイー オレオ ゲーエムベーハー | 成形体への圧縮を目的とした粉末材料用添加剤 |
| TW202039443A (zh) * | 2019-01-04 | 2020-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | ６－側氧基－１，６－二氫噠嗪類衍生物、其製備方法及其在醫藥上的應用 |
| WO2020169042A1 (zh) * | 2019-02-20 | 2020-08-27 | 江苏恒瑞医药股份有限公司 | 6-氧代-1,6-二氢哒嗪类前药衍生物、其制备方法及其在医药上的应用 |
| WO2021198534A1 (en) | 2020-04-04 | 2021-10-07 | Oxurion NV | Plasma kallikrein inhibitors for use in the treatment of coronaviral disease |
| WO2023148016A1 (en) | 2022-02-04 | 2023-08-10 | Oxurion NV | Biomarker for plasma kallikrein inhibitor therapy response |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI259079B (en) * | 2002-02-08 | 2006-08-01 | Merck & Co Inc | N-biphenyl(substituted methyl)aminocycloalkanecarboxamide derivatives |
| EP1545538A2 (en) * | 2002-08-29 | 2005-06-29 | Merck & Co., Inc. | N-biarylmethyl aminocycloalkanecarboxamide derivatives |
| AU2004265300A1 (en) * | 2003-08-07 | 2005-02-24 | Merck & Co., Inc. | Sulfonyl substituted N-(biarylmethyl) aminocyclopropanecarboxamides |
| WO2005085198A2 (en) * | 2004-03-02 | 2005-09-15 | Merck & Co., Inc. | Amino cyclopropane carboxamide derivatives as bradykinin antagonists |
| US20080221111A1 (en) | 2005-05-11 | 2008-09-11 | Nycomed Gmbh | Combination of a Pd4 Inhibitor and a Tetrahydrobiopterin Derivative |
| HUP0600809A3 (en) * | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them |
| RS52801B (sr) | 2009-02-26 | 2013-10-31 | Boehringer Ingelheim International Gmbh | Jedinjenja kao antagonisti bradikinina-b1 |
| ES2531663T7 (es) | 2010-02-23 | 2018-02-13 | Boehringer Ingelheim International Gmbh | Compuestos en calidad de antagonistas de bradiquinina B1 |
-
2011
- 2011-02-21 ES ES11705858.6T patent/ES2531663T7/es active Active
- 2011-02-21 PT PT117058586T patent/PT2539323E/pt unknown
- 2011-02-21 WO PCT/EP2011/052512 patent/WO2011104203A1/de not_active Ceased
- 2011-02-21 CA CA2790952A patent/CA2790952C/en not_active Expired - Fee Related
- 2011-02-21 MX MX2012009224A patent/MX2012009224A/es active IP Right Grant
- 2011-02-21 SG SG2012060620A patent/SG183336A1/en unknown
- 2011-02-21 DK DK11705858.6T patent/DK2539323T6/en active
- 2011-02-21 PL PL11705858T patent/PL2539323T6/pl unknown
- 2011-02-21 AU AU2011219885A patent/AU2011219885C1/en not_active Ceased
- 2011-02-21 SI SI201130402T patent/SI2539323T1/sl unknown
- 2011-02-21 MA MA35153A patent/MA34008B1/fr unknown
- 2011-02-21 JP JP2012553341A patent/JP5603955B2/ja active Active
- 2011-02-21 EP EP11705858.6A patent/EP2539323B3/de active Active
- 2011-02-21 AP AP2012006330A patent/AP3218A/xx active
- 2011-02-21 KR KR1020127021929A patent/KR101843341B1/ko not_active Expired - Fee Related
- 2011-02-21 NZ NZ601194A patent/NZ601194A/en not_active IP Right Cessation
- 2011-02-21 CN CN201180009563.1A patent/CN102781916B/zh not_active Expired - Fee Related
- 2011-02-21 PE PE2012001250A patent/PE20121805A1/es not_active Application Discontinuation
- 2011-02-21 CN CN201410206948.2A patent/CN103980258B/zh not_active Expired - Fee Related
- 2011-02-22 TW TW100105851A patent/TWI499589B/zh active
- 2011-02-22 AR ARP110100542A patent/AR080249A1/es not_active Application Discontinuation
-
2012
- 2012-06-28 IL IL220680A patent/IL220680A/en not_active IP Right Cessation
-
2015
- 2015-03-02 CY CY20151100211T patent/CY1116182T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2012000417A1 (en) | Compounds as bradykinin b1 antagonists | |
| MX2012009224A (es) | Compuestos en calidad de antagonistas de bradiquinina-b1. | |
| AU2011274192A8 (en) | Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof | |
| MX2014014229A (es) | Pirrolidina-2-carboxamidas sustituidas. | |
| MY162535A (en) | Inhibitors of arginase and their therapeutic applications | |
| PH12012501546A1 (en) | Substituted pyrrolidine-2-carboxamides | |
| GEP201606555B (en) | Compounds and compositions for modulating egfr activity | |
| SG195106A1 (en) | Trpv4 antagonists | |
| IL204437A (en) | History of aryl cyclic profile and their use | |
| MY169986A (en) | Benzimidazole-proline derivatives | |
| TW201129565A (en) | Tricyclic heterocyclic compounds, compositions and methods of use thereof | |
| IN2012DN03337A (es) | ||
| EA201201050A1 (ru) | Пиразолы в качестве антагонистов crth2 | |
| PH12014501542A1 (en) | Substituted pyrrolidine -2- carboxamides | |
| MX340233B (es) | Agonistas de receptores de neurotrofina y sus usos como medicamentos. | |
| PH12013500942A1 (en) | Triazolopyridine compounds | |
| GB201209587D0 (en) | Therapeutic compounds | |
| MX2010009927A (es) | Derivados de espiroindolinona. | |
| PH12015501386A1 (en) | Tricyclic compounds | |
| WO2014062838A3 (en) | Pkm2 modulators and methods for their use | |
| IN2012DN01232A (es) | ||
| PH12013500330A1 (en) | Disubstituted tetrahydofuranyl compounds as antagonists of the bradykinin b1 receptor | |
| GEAP201814272A (en) | Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists | |
| GB0602951D0 (en) | Organic Compounds | |
| PH12012501521A1 (en) | 5-alkynyl pyrimidines and their use as kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |